Literature DB >> 8701885

Comparison of elective Wiktor stent placement with conventional balloon angioplasty for new-onset lesions of the right coronary artery.

E Eeckhout1, J C Stauffer, P Vogt, N Debbas, L Kappenberger, J J Goy.   

Abstract

This study compared the clinical and angiographic outcome, during a 6-month follow-up period, of 84 patients with new-onset lesions of the right coronary artery randomized to either Wiktor stent implantation (42 patients) or conventional balloon angioplasty (42 patients). At hospital discharge, three patients in each group (7%, p = not significant [NS]) reached a clinical end point. At 6 months, these proportions were 24% (10 patients with stents) and 29% (12 patients with angioplasty) (p = NS). There were no incidents of death or myocardial infarction. Despite a larger minimal luminal diameter after stenting (2.87 mm [95% confidence interval; 2.66 to 2.96 mm] vs 2.37 mm [2.23 to 2.61 mm for angioplasty] [p = 0.001]), no difference was observed at 6 months of follow-up (1.75 mm [1.43 to 2.18 mm] vs 1.74 mm [1.45 to 2.03 mm] [p = NS], respectively). Accordingly, angiographic restenosis rates were 47.5% (19 of 40 patients with stents) and 35% (14 of 40 patients with angioplasty) (p = NS). Elective stenting with the Wiktor stent and conventional balloon angioplasty are safe and immediately effective therapeutic options for symptomatic, obstructive right coronary artery disease. At 6 months of follow-up, clinical and angiographic outcome did not differ. The role of Wiktor stent placement in primary restenosis prevention remains to be determined for lesions of the right coronary artery.

Entities:  

Mesh:

Year:  1996        PMID: 8701885     DOI: 10.1016/s0002-8703(96)90420-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  1 in total

1.  Are "treatment" bare metal stents superior to "control" bare metal stents? A meta-analytic approach.

Authors:  David M Kent; Thomas A Trikalinos
Journal:  Am Heart J       Date:  2008-01-18       Impact factor: 4.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.